April 27 Danish drug maker Novo Nordisk A/S says:
* Receives approval of Saxenda (liraglutide) injection 3 mg label update including long-term safety and efficacy data from 3-year trial from U.S. Food and Drug Administration
* "We are pleased by the FDA's approval, which marks Saxenda as the only weight-loss and management medicine in a pen supported by long-term safety and efficacy data," says Dr. Todd Hobbs, vice president and chief medical officer at Novo Nordisk U.S.
* For more on the data: Further company coverage: (Reporting by Stine Jacobsen)
Meal-kit maker Blue Apron lowers expected IPO price range
June 28 Online meal-kit company Blue Apron Holdings slashed the expected pricing range for its initial public offering to between $10 and $11 per share from its previous expectation of $15 to $17 per share.
BRIEF-Unterberg Capital says engaging in discussions with Fusion Teleco management, board about board representation
June 28 Fusion Telecommunications International Inc: